Company Market Research Report: eversyn GmbH

---

Company Overview

• Name: eversyn GmbH

• Mission: To leverage cutting-edge biotechnology to make vital glycan molecules accessible at both research and industrial scales, thereby unlocking their potential for groundbreaking discoveries and innovations in nutrition and biopharma.

• Founded By: Scientists and business professionals associated with the Max Planck Society.

• Headquarters: OVGU Building 25, Universitätsplatz 2, DE-39106 Magdeburg, Germany.

• Key People:

• Dr. Thomas Rexer - Managing Director

• Rachel Thu Nguyen - Chief Business Officer

• Dr. Nam-Hai Hoang - Principal Scientist Biocatalysis

• Dr. Karim Jaén - R&D Director In Vitro Engineering

• Sebastian Bruno Kleeberg - Head of Production

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Being a spin-off from the Max Planck Institute, specializing in the production of activated sugars and glycoengineering tools, with significant contributions to the field of human milk oligosaccharides (HMOs).

Products

Activated Sugars

• Description: Essential intermediates in biochemical processes, playing a critical role in glycosylation reactions necessary for therapeutic and nutritional applications.

• Key Features:

• Affordably priced from €220 for research applications.

• Include UDP-GlcNAc, UDP-galactose, and CMP-N-Acetylneuraminic Acid.

• Available in stock for 100mg to 1g, with price guarantees.

Enzymes for In Vitro Glycoengineering

• Description: Serve the purpose of gaining control over protein glycosylation and glycan engineering through biocatalysis and glycoanalytics.

• Key Features:

• Priced from €390, available up to 500 units.

• Used in synthesis of glycoconjugates.

Human Milk Oligosaccharides (HMOs)

• Description: Diverse glycans found in human milk, significant for infant nutrition and health, with applications explored beyond early life stages.

• Key Features:

• Developed using cell-free synthesis outside living cells for enhanced enzyme precision.

Recent Developments

• New Products Launched: No new product launches reported.

• New Features Added: Implementation of robust and scalable production processes for glycosyltransferases to strengthen their glycoengineering platform.

• Partnerships and Collaborations:

• Partnered with FrieslandCampina in TKI Research Consortium (April 2024) to explore the effects of HMOs on the immune system and intestinal epithelium.

• Accepted into Plug and Play's Accelerator Batch 15 (April 2024), leveraging exclusive workshops and mentor sessions.

• Supporting organization of GlycoBioTec2025 (August 2024).

• Participation in Events:

• Significant presence at numerous global events including the BIO-Europe Spring 2024, Future Food Tech in London (September 2023), and the Festival of Biologics in Basel, Switzerland (October 2023).

• Corporate Updates:

• Appointment of Dr. Ing. Volker Landschütze as interim CEO (July 2023).

• Secured a grant over 0.9 Mio € for technology and business development (January 2022).

Summary

eversyn GmbH stands as a dynamic biotech enterprise emerging from the Max Planck Institute, channeling expertise into the field of glycan biotechnology. With strong product offerings in activated sugars and enzymes, alongside significant advancements in HMOs, eversyn is poised for influential contributions to nutrition and biopharma, evidenced by strategic partnerships and consistent participation in industry forums.